{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-26-002410","form_type":"8-K","ticker":"IGC","cik":"0001326205","company_name":"IGC Pharma, Inc.","filed_at":"2026-06-08T20:03:16+00:00","discovered_at":"2026-06-08T20:04:00.256265+00:00","generated_at":"2026-06-08T20:04:49.799599+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"IGC Pharma extends $12M loan agreement with O-Bank; facility fee rises to $60,000","bullets":["Entered amendment to extend Master Loan and Security Agreement with O-Bank Co., Ltd.","Facility maximum aggregate limit remains $12,000,000 unchanged from 2025.","Facility fee increased from $48,000 to $60,000; other terms substantially unchanged.","Loan agreement continues the general banking facility arrangement originally dated June 24, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002410","json":"https://secwatch.observer/filing/0001185185-26-002410.json","markdown":"https://secwatch.observer/filing/0001185185-26-002410.md","text":"https://secwatch.observer/filing/0001185185-26-002410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526002410/0001185185-26-002410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526002410/igc8k060826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T20:04:49.799599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c2c0f58de8a785ee600442fd2aedabf16fc4747","claim":"IGC Pharma, Inc. entered into Amendment to Master Loan and Security Agreement with O-Bank Co., Ltd. valued at Facility limit of $12,000,000; facility fee increased from $48,000 to $60,000 (effective 2026-06-05).","evidence_excerpt":"On June 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into an amendment to extend its existing Master Loan and Security Agreement together with the General Banking Facility Letter (collectively, the “Loan Agreement”) with O-Bank Co., Ltd., a banking corporation incorporated under the laws of Taiwan, as lender (the “Lender”). The Loan Agreement continues the facility arrangement previously set forth in the General Banking Facility Letter dated June 24, 2025. The facility provides for a maximum aggregate limit of $12,000,000. The material terms of the facility remain substantially unchanged from the 2025 facility letter, except that the facility fee has increased from $48,000 to $60,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526002410/0001185185-26-002410-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"O-Bank Co., Ltd."},{"label":"Value","value":"Facility limit of $12,000,000; facility fee increased from $48,000 to $60,000"},{"label":"Effective","value":"2026-06-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}